




The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 38% points. The greatest weakness of PUMA Biotechnology INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 159% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 72% points below the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	134,281	Assets	222,059
Cost of Goods Sold	55,093	Liabilities	200,451
Intangible Assets	0	Expenses	204,766
Liabilities, Current	77,484	Revenues	228,031
Liabilities, Non-Current	110,141	Stockholders Equity	21,608
Other Assets	86,632	Net Income	23,265
Other Compr. Net Income	2.0	Comprehensive Net Income	23,266
Other Expenses	7,455	BaseVar	427,654
Other Liabilities	12,826	ECR before LimitedLiability	33%
Other Net Income	0	Economic Capital Ratio	173%
Other Revenues	228,031		
Property and Equipment	1,146		
Research and Development	52,240		
Selling, General and Administrative Expense	89,978		